studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 1259A
larger generalized population. Conclusions: The combination
of serum Fuc-Hpt and Mac2bp can distinguish NASH from
NAFLD patients. Our noninvasive model using serum two glycobiomarkers
contribute to a novel NASH diagnostic methodology
instead of liver biopsy.
Disclosures:
Yoshito Itoh - Grant/Research Support: MSD KK, Bristol-Meyers Squibb, Dainippon
Sumitomo Pharm. Co., Ltd., Otsuka Pharmaceutical Co., Chugai Pharm
Co., Ltd, Mitsubish iTanabe Pharm. Co.,Ltd., Daiichi Sankyo Pharm. Co.,Ltd.,
Takeda Pharm. Co.,Ltd., AstraZeneca K.K.:, Eisai Co.,Pharm.Ltd, FUJIFILM Medical
Co.,Ltd., Gelaed Sciences Co., GlaxoSmithKline
Norifumi Kawada - Grant/Research Support: BMS, Chugai, Kowa; Speaking
and Teaching: MSD, Janssen
Kazuaki Chayama - Consulting: AbbVie; Grant/Research Support: Ajinomoto,
Astellas, Torii, Tsumura, Aska, Bayer, Zeria, Daiichi Sankyo, Dainippon Sumitomo,
Eisai, Eli Lily, Janssen, Kowa, Mitsubishi Tanabe, MSD, Nippon Kayaku,
Nippon Shinyaku, Otsuka, Roche, Takeda, Toray; Speaking and Teaching:
Ajinomoto, AbbVie, Abott, Astellas, AstraZeneca, Aska, Bayer, BMS, Chugai,
Daiichi Sankyo, Dainippon Sumitomo, Eisai, J & J, Jimro, Miyarisan, MSD, Nihon
Kayaku, Olympus
Tetsuo Takehara - Grant/Research Support: Chugai Pharmaceutical Co., MSD
K.K., Bristol-Meyer Squibb, Mitsubishi Tanabe Pharma Corparation, Toray Industories
Inc. ; Speaking and Teaching: MSD K.K., Bristol-Meyer Squibb, Janssen
Pharmaceutical Companies
The following authors have nothing to disclose: Yoshihiro Kamada, Masafumi
Ono, Hideyuki Hyogo, Hideki Fujii, Yoshio Sumida, Kohjiroh Mori, Saiyu
Tanaka, Makoto Yamada, Maaya Akita, Kayo Mizutani, Hironobu Fujii, Akiko
Yamamoto, Shinji Takamatsu, Yuichi Yoshida, Toshiji Saibara, Eiji Miyoshi
2157
Increased Immune Responses of Patients with Lean
Non-Alcoholic Fatty Liver Diseases Over Obese Non-Alcoholic
Fatty Liver Diseases in Response to Saturated
Fatty Acid
Ayub Al Mamun 2 , Mamun A. Mahtab 2 , Sheikh Mohammad Fazle
Akbar 1 ; 1 Department of Medical Sciences, Toshiba General Hospital,
Tokyo, Japan; 2 Department of Hepatology, Bangbandhu
Sheikh Mujib Medical University, Dhaka, Bangladesh
Purpose: To develop insights about mechanism of pathogenesis
of obesity in lean persons, this study was initiated to dissect
immunological events in lean patients with non-alcoholic fatty
liver diseases (NAFLD) versus obese patients with NAFLD. Methods:
Out of total 450 patients with NAFLD, clinical parameters
of age and sex-matched 50 patients with lean NAFLD (body
mass index (body mass index, BMI) 30.0) were compared. Peripheral
blood mononuclear cells (PBMC) and antigen-presenting dendritic
cells (DC) from both lean NAFLD and obese NAFLD
patients were isolated and production of pro-inflammatory cytokines
and nitric oxide (NO) in response to various stimuli were
evaluated. Results: As mentioned, the BMI of lean NAFLD patents
were significantly lower than that of obese NAFLD patients
(p0.05). The levels of proinflammatory cytokines [interferon
(IFN)-gamma, tumor necrosis factor (TNF)-alpha, and interleukin
(IL)-6] produced by PBMC and DC were also comparable
between lean NAFLD and obese NAFLD patients when these
were stimulated by polyclonal stimulators like concanavalin
A or lipopolysachcharides (p>0.05). However, significantly
higher levels of IFN-gamma, TNF-alpha, and IL-6 were produced
by PBMC and DC of lean NAFLD patients compared to
those produced by obese NAFLD patients in response to palmitic
acid (p0.05).
This outcome was reproducible in three separate experiments
with sera collected at three separate points. Also, nitric oxide
(NO) production was significantly higher from PBMC of lean
NAFLD patients compared to obese NAFLD patients (p